Drug Trial Radar · NCT02631876
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
Last checked: Nov 20, 2026Latest source record: Oct 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
366
Actual
Start
Mar 2, 2016
Primary completion
Jan 2019
Study completion Jan 2020
Sponsor
- Lead sponsor
- ImmunoGen, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Gynecologic Oncology Group
- First posted
- Dec 16, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer.
Conditions
- Epithelial Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
- Ovarian Cancer
Interventions
Mirvetuximab soravtansineDrug
Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.
PaclitaxelDrug
Paclitaxel will be administered per dose and schedule specified in the arm.
Pegylated liposomal doxorubicinDrug
Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
TopotecanDrug
Topotecan will be administered per dose and schedule specified in the arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS), as Assessed by BIRC Per RECIST Version 1.1 in All Participants Randomized to the StudyTime frame: From the date of randomization until the time of death or PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
- PFS, as Assessed by BIRC Per RECIST Version 1.1 in Participants With High Folate Receptor Alpha Level (≥ 75% of Tumor Staining)Time frame: From the date of randomization until the time of death or PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
Locations
131 sites in 13 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Arizona Oncology Associates, PC - HAL
Tempe, Arizona
Arizona Oncology Associates, PC - HOPE
Tucson, Arizona
UCLA Women's Health Clinical Research Unit - OBGYN
Los Angeles, California
University of California San Diego Medical Center
San Diego, California
California Pacific Medical Center
San Francisco, California
Kaiser Permanente Medical Center
Vallejo, California
Yale University School of Medicine
New Haven, Connecticut
Norwalk Hospital/WCHN
Norwalk, Connecticut
Florida State University College of Medicine
Sarasota, Florida
Georgia Regents University (GRU)-Medical College of Georgia (MCG) - Cancer Center
Augusta, Georgia
Rush University Medical Center
Chicago, Illinois
Sudarshan Sharma LTD
Hinsdale, Illinois
Community Health Network, Inc.
Indianapolis, Indiana
Indiana University School of Medicine
Indianapolis, Indiana
Norton Cancer Institute
Louisville, Kentucky
Women's Cancer Care
Covington, Louisiana
Ochsner Clinic Foundation
New Orleans, Louisiana
WK Physician Network Clinical Research
Shreveport, Louisiana
Holy Cross Hospital
Silver Spring, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Henry Ford Hospital
Detroit, Michigan
Mercy Women's Oncology
Springfield, Missouri
Center of Hope
Reno, Nevada
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
MD Anderson Cancer Center - Cooper Health
Camden, New Jersey
Overlook Medical Center
Summit, New Jersey
The University of New Mexico Comprehensive Cancer Center - Memorial Medical Center
Albuquerque, New Mexico
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Memorial Sloan Kettering Cancer Center and (MSK Monmouth) and ( MSK Westchester)
New York, New York
Levine Cancer Institute - Carolinas Medical Center
Charlotte, North Carolina
University of Cincinnati Medical Center
Cincinnati, Ohio
Fairview Hospital, Moll Pavilion Cancer Center
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
OSU Wexner Medical Center
Columbus, Ohio
Hillcrest Hospital
Mayfield, Ohio
Showing 40 of 131 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.